Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2011

View Archived Issues

Novel orexin receptor antagonists described by Merck & Co.

New free fatty acid FFA1 receptor agonists disclosed

Phase IIa study shows no appreciable difference between SYN-118 and placebo in Parkinson's disease

Genasense does not improve survival of dacarbazine-treated patients with melanoma in phase III trial

SLC23A1 gene SNP correlates with neovascular age-related macular degeneration

AZD-3199 has long-lasting bronchoprotective activity in vivo

Scientists identify alpha-1-antitrypsin as marker of cutaneous squamous cell carcinoma progression

Gene therapy JVS-100 is safe in patients with heart failure after myocardial infarction

Pfizer designs new sodium/glucose cotransporter 2 inhibitors

Anavex advances Alzheimer's disease candidate ANAVEX 2-73 to higher dose in phase I trial

Lilly forms new critical care company BioCritica

Mutations in CACNA2D1 gene may confer susceptibility to Brugada syndrome

Provectus Pharmaceuticals completes accrual in phase IIc PH-10 trial in psoriasis

Ampio Pharmaceuticals completes evaluation of phase III data on Zertane

Merck & Co. presents new NO-linked cicletanine and derivatives

NovaBay's NVC-422 shows promise in patients with epidemic keratoconjunctivitis

Novel erythropoietin production enhancers presented by Daiichi Sankyo

Prometheus to be acquired by Nestle Health Science

Preclinical study of Proteonomix's UMK-121 suggests ability to mobilize stromal stem cells

Toxicology studies completed for Alzheimer's disease drug candidate SUVN-502

FDA sets PDUFA date for fentanyl sublingual spray NDA review

FDA advisory committee to discuss Regeneron's BLA for VEGF Trap-Eye in June

Basilea Pharmaceutica reports topline data from first phase I trial of BAL-30072

Eisai and University College London to conduct joint research in neurodegenerative disease

CHMP issues negative trend vote on Bronchitol for cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...